Residual Exacerbations With Mepolizumab

Laval University

Status

Enrolling

Conditions

Asthma

Treatments

Drug: Mepolizumab

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT04578171

CÉR21903

Details and patient eligibility

About

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Full description

Before initiation of mepolizumab, a recording of patient's demographics, clinical, physiological and inflammatory features will be recorded. All subjects will be reassessed for the above measures at 6, 12, 18 and 24 months.

In addition to the above visits, patients will be assessed every time they experience either moderate or severe exacerbation of asthma over the treatment period.

Based on the percentage of sputum eosinophils and neutrophils, the type of inflammatory exacerbation will be determined

Enrollment

60 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
Eligible for mepolizumab treatment
Able and willing to sign the informed consent form

Exclusion criteria

Any respiratory disease apart from asthma
Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome